Spots Global Cancer Trial Database for relapse multiple myeloma
Every month we try and update this database with for relapse multiple myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma | NCT03143049 | Relapse Multipl... | PCD PD | 21 Years - 99 Years | National University Hospital, Singapore | |
| A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma | NCT04918511 | Relapse Multipl... Multiple Myelom... | OPD5 | 18 Years - | Oncopeptides AB | |
| Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib | NCT01775553 | Relapse Multipl... Refractory Mult... | Carfilzomib | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | NCT05430945 | Relapse Multipl... Refractory Mult... | BCMA Targeted C... | - | Zhejiang University | |
| Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | NCT05789303 | Multiple Myelom... Relapse Multipl... | Belantamab mafo... Carfilzomib Pomalidomide Dexamethasone | 18 Years - | University of Chicago | |
| B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | NCT05150522 | Multiple Myelom... Relapse Multipl... Refractory Mult... | BCMA CAR-T cell... | 18 Years - 75 Years | Shenzhen University General Hospital | |
| B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | NCT05150522 | Multiple Myelom... Relapse Multipl... Refractory Mult... | BCMA CAR-T cell... | 18 Years - 75 Years | Shenzhen University General Hospital | |
| Descartes-25 in Relapsed/Refractory Multiple Myeloma | NCT05113342 | Multiple Myelom... Relapse Multipl... | Descartes-25 | 18 Years - | Cartesian Therapeutics | |
| INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma | NCT04355039 | Refractory Mult... Relapse Multipl... | Pomalidomide Dexamethasone INCB053914 50 m... INCB053914 65 m... INCB053914 80 m... | 18 Years - | Medical College of Wisconsin | |
| Horizon Adaptive Platform Trial Evaluating Therapies in RRMM | NCT06171685 | Relapse Multipl... Refractory Mult... | Teclistamab Investigational... | 18 Years - 99 Years | Multiple Myeloma Research Consortium | |
| INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma | NCT04355039 | Refractory Mult... Relapse Multipl... | Pomalidomide Dexamethasone INCB053914 50 m... INCB053914 65 m... INCB053914 80 m... | 18 Years - | Medical College of Wisconsin | |
| A Study of MCARH109 and MCARH125 in People With Multiple Myeloma | NCT05431608 | Multiple Myelom... Refractory Mult... Relapse Multipl... | MCARH125 MCARH109 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT05117008 | Refractory Mult... Relapse Multipl... | Belantamab mafo... | 18 Years - | Medical College of Wisconsin | |
| Multiple Myeloma Turkish Prospective Patient Registry | NCT04143932 | Multiple Myelom... Relapse Multipl... | 18 Years - | Turkish Hematology Association | ||
| Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma | NCT05789303 | Multiple Myelom... Relapse Multipl... | Belantamab mafo... Carfilzomib Pomalidomide Dexamethasone | 18 Years - | University of Chicago | |
| Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma | NCT03143049 | Relapse Multipl... | PCD PD | 21 Years - 99 Years | National University Hospital, Singapore | |
| INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma | NCT04355039 | Refractory Mult... Relapse Multipl... | Pomalidomide Dexamethasone INCB053914 50 m... INCB053914 65 m... INCB053914 80 m... | 18 Years - | Medical College of Wisconsin | |
| A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab | NCT04302324 | Multiple Myelom... Refractory Mult... Relapse Multipl... | Daratumumab SC Clarithromycin Pomalidomide Dexamethasone | 18 Years - 75 Years | Weill Medical College of Cornell University | |
| B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | NCT05150522 | Multiple Myelom... Relapse Multipl... Refractory Mult... | BCMA CAR-T cell... | 18 Years - 75 Years | Shenzhen University General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
